Background: Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients' cohorts, one treated with lomitapide in Italy (n = 30) and the other with LA in France (n = 29). Results: The two cohorts differed significantly for genotype (p = 0.004), baseline lipid profile (p < 0.001), age of treatment initiation (p < 0.001), occurrence of cardiovascular disease (p = 0.003) as well as follow-up duration (p < 0.001). The adjunct of lomitapide to conventional lipid-lowering therapies determined an additional 58.0% reduction of last visit LDL-C levels, compared to 37.1% when LA was added (padj = 0.004). Yearly on-treatment LDL-C < 70 mg/dl and < 55 mg/dl goals were only achieved in 45.5% and 13.5% of HoFH patients treated with lomitapide. The long-term exposure to LDL-C burden was found to be higher in LA than in Lomitapide cohort (13,236.1 ± 5492.1 vs. 11,656.6 ± 4730.9 mg/dL-year respectively, padj = 0.002). A trend towards fewer total cardiovascular events was observed in the Lomitapide than in the LA cohort. Conclusions: In comparison with LA, lomitapide appears to provide a better control of LDL-C in HoFH. Further studies are needed to confirm this data and establish whether this translates into a reduction of cardiovascular risk.

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey / D'Erasmo, L; Gallo, A; Cefalù, Ab; Di Costanzo, A; Saheb, S; Giammanco, A; Averna, M; Buonaiuto, A; Iannuzzo, G; Fortunato, G; Puja, A; Montalcini, T; Pavanello, C; Calabresi, L; Vigna, Gb; Bucci, M; Bonomo, K; Nota, F; Sampietro, T; Sbrana, F; Suppressa, P; Sabbà, C; Fimiani, F; Cesaro, A; Calabrò, P; Palmisano, S; D'Addato, S; Pisciotta, L; Bertolini, S; Bittar, R; Kalmykova, O; Béliard, S; Carrié, A; Arca, M; Bruckert, E.. - In: ORPHANET JOURNAL OF RARE DISEASES. - ISSN 1750-1172. - 16:1(2021). [10.1186/s13023-021-01999-8]

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

D'Erasmo L
Co-primo
;
Di Costanzo A
Secondo
;
Iannuzzo G;Arca M
Penultimo
;
2021

Abstract

Background: Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients' cohorts, one treated with lomitapide in Italy (n = 30) and the other with LA in France (n = 29). Results: The two cohorts differed significantly for genotype (p = 0.004), baseline lipid profile (p < 0.001), age of treatment initiation (p < 0.001), occurrence of cardiovascular disease (p = 0.003) as well as follow-up duration (p < 0.001). The adjunct of lomitapide to conventional lipid-lowering therapies determined an additional 58.0% reduction of last visit LDL-C levels, compared to 37.1% when LA was added (padj = 0.004). Yearly on-treatment LDL-C < 70 mg/dl and < 55 mg/dl goals were only achieved in 45.5% and 13.5% of HoFH patients treated with lomitapide. The long-term exposure to LDL-C burden was found to be higher in LA than in Lomitapide cohort (13,236.1 ± 5492.1 vs. 11,656.6 ± 4730.9 mg/dL-year respectively, padj = 0.002). A trend towards fewer total cardiovascular events was observed in the Lomitapide than in the LA cohort. Conclusions: In comparison with LA, lomitapide appears to provide a better control of LDL-C in HoFH. Further studies are needed to confirm this data and establish whether this translates into a reduction of cardiovascular risk.
2021
cholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeutics
01 Pubblicazione su rivista::01a Articolo in rivista
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey / D'Erasmo, L; Gallo, A; Cefalù, Ab; Di Costanzo, A; Saheb, S; Giammanco, A; Averna, M; Buonaiuto, A; Iannuzzo, G; Fortunato, G; Puja, A; Montalcini, T; Pavanello, C; Calabresi, L; Vigna, Gb; Bucci, M; Bonomo, K; Nota, F; Sampietro, T; Sbrana, F; Suppressa, P; Sabbà, C; Fimiani, F; Cesaro, A; Calabrò, P; Palmisano, S; D'Addato, S; Pisciotta, L; Bertolini, S; Bittar, R; Kalmykova, O; Béliard, S; Carrié, A; Arca, M; Bruckert, E.. - In: ORPHANET JOURNAL OF RARE DISEASES. - ISSN 1750-1172. - 16:1(2021). [10.1186/s13023-021-01999-8]
File allegati a questo prodotto
File Dimensione Formato  
D'Erasmo_Long-term efcacy_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.48 MB
Formato Adobe PDF
1.48 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1667961
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact